Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

NCRM, CSCRM to become national force in regenerative medicine

In a move to streamline and accelerate the research and development of new stem cell and regenerative medicine technologies, the National Center for Regenerative Medicine and the Center for Stem Cell and Regenerative Medicine at Case Western Reserve University have been rolled into a single entity housed within the university's School of Medicine.

5 Mar 2011

CDI announces publication of footprint-free iPSCs production method in PLoS ONE journal

Cellular Dynamics International, the world's largest producer of human tissue cells for drug discovery and safety testing, today announced the publication of research demonstrating an efficient and scalable method of creating DNA integration-free, or footprint-free, induced pluripotent stem cells under a feeder-free condition using chemically defined media.

5 Mar 2011

Shares of Bacterin's common stock receive approval for listing on NYSE Amex

Bacterin International Holdings, Inc., a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that its common stock has been approved for listing on the NYSE Amex and has chosen Knight Capital Group as its designated market maker.

5 Mar 2011

Scientists detail role of TDP-43 in ALS pathology

Amyotrophic lateral sclerosis, known as ALS or more popularly, Lou Gehrig's disease, is a notorious neurodegenerative condition characterized by the progressive deterioration of brain and spinal cord neurons, resulting in the gradual but catastrophic loss of muscle control and ultimately, death.

5 Mar 2011

ThermoGenesis prices offering of 2,250,000 shares of common stock

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today that it has determined the pricing for an offering of shares and warrants.

4 Mar 2011

CBAI modifies authorized shares from pro-rata 500 to 250 million

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that the Company's management team and board of directors has modified the proposed one share for each 500 outstanding shares reverse stock split to one share for each 100 outstanding shares.

4 Mar 2011

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Sangamo BioSciences, Inc. announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections, held in Boston from February 27 to March 2, 2011.

4 Mar 2011

Researchers transform human embryonic stem cell into neuron that dies early in Alzheimer's disease

Northwestern Medicine researchers for the first time have transformed a human embryonic stem cell into a critical type of neuron that dies early in Alzheimer's disease and is a major cause of memory loss.

4 Mar 2011

Executioner enzyme may short circuit second form of cell death

An enzyme viewed as an executioner, because it can push cells to commit suicide, may actually short circuit a second form of cell death, researchers at Emory University School of Medicine have discovered.

4 Mar 2011

Stem cell research updates

Two studies have been published this Wednesday in the journal Nature that show that work remains before so-called induced pluripotent stem (iPS) cells are ready for use in laboratory studies or clinical therapies. These iPS cells are body cells that are programmed to unwind back into an embryonic state. Like embryonic stem cells, they have potential to develop into any other type of cell in the body. However researchers are showing that these cells do not reprogram perfectly.

3 Mar 2011

Scientist receives $4 million Australia fellowship to continue cancer origin research

Walter and Eliza Hall Institute cancer researcher Professor Jane Visvader has received a $4 million fellowship from the Australian Government to continue her work into the origin of breast, ovarian and lung cancers.

3 Mar 2011

Scientists find reprogramming-associated mutations in hiPSCs

Ordinary human cells reprogrammed as induced pluripotent stem cells may ultimately revolutionize personalized medicine by creating new and diverse therapies unique to individual patients.

3 Mar 2011

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

Vical Incorporated announced today the receipt of Scientific Advice from the European Medicines Agency (EMA) recommending practical efficacy endpoints for a Phase 3 trial of the company's TransVax™ therapeutic cytomegalovirus (CMV) vaccine.

3 Mar 2011

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

Osiris Therapeutics, Inc., today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack.

3 Mar 2011

Scientists discover specific type of human cell to treat spinal cord injuries

For the first time, scientists discovered that a specific type of human cell, generated from stem cells and transplanted into spinal cord injured rats, provide tremendous benefit, not only repairing damage to the nervous system but helping the animals regain locomotor function as well.

2 Mar 2011

Cellastim and Optiferrin enable development of xeno-free and blood product-free expansion media

A recent study demonstrated that Cellastim and Optiferrin deliver superior xeno-free and animal-free solutions for primary cell and stem cell expansion media.

2 Mar 2011

Cord Blood America purchases all UCB samples and related lab equipment from RGI

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company, focused on bringing the life saving potential of cord blood stem cells to families nationwide and internationally, announced today that it has purchased all the umbilical cord blood samples and the related laboratory equipment from Reproductive Genetics Institute, Inc., based in Chicago, Illinois.

2 Mar 2011

NEI/FDA conference to analyze functional vision outcomes from clinical trials of visual prostheses

The National Eye Institute and Food and Drug Administration are sponsoring a conference to determine how functional vision-related endpoints for clinical trials of visual prostheses will be analyzed and correlated with objective measures of visual acuity, visual fields and contrast sensitivity.

2 Mar 2011

Mathematical model predicts lifespan of stem cells

When patients receive a bone marrow transplant, they are getting a new population of hematopoietic stem cells. Fresh stem cells are needed when a patient is low on red blood cells, as in anemia, or white blood cells, which can be caused by cancer or even cancer treatments such as irradiation or chemotherapy. The problem is that a bone marrow transplant might not succeed because the transplanted stem cells don't live long enough or because they proliferate too well, leading to leukemia.

2 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

Stem Cells News and Research

Further Reading

NCRM, CSCRM to become national force in regenerative medicine

CDI announces publication of footprint-free iPSCs production method in PLoS ONE journal

Shares of Bacterin's common stock receive approval for listing on NYSE Amex

Scientists detail role of TDP-43 in ALS pathology

ThermoGenesis prices offering of 2,250,000 shares of common stock

CBAI modifies authorized shares from pro-rata 500 to 250 million

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Researchers transform human embryonic stem cell into neuron that dies early in Alzheimer's disease

Executioner enzyme may short circuit second form of cell death

Stem cell research updates

Scientist receives $4 million Australia fellowship to continue cancer origin research

Scientists find reprogramming-associated mutations in hiPSCs

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

Scientists discover specific type of human cell to treat spinal cord injuries

Cellastim and Optiferrin enable development of xeno-free and blood product-free expansion media

Cord Blood America purchases all UCB samples and related lab equipment from RGI

NEI/FDA conference to analyze functional vision outcomes from clinical trials of visual prostheses

Mathematical model predicts lifespan of stem cells

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo